Skip to content
ATLAS PREP HQ
Longevity

Vesugen

Lys-Glu-Asp (KED) ultrashort vascular peptide bioregulator

Peptide bioregulator research focused on vascular endothelial function and gene-regulation pathways.

Preclinical Evidence

Route

Subcutaneous in the community educational protocol.

Common format

20 mg vial

Research focus

vascular endothelium

Evidence level

Preclinical Evidence

Typical cycle

8–12 weeks

Longevity research motifLongevity

Vesugen in 30 seconds

Atlas Fast Read

What it is

Lys-Glu-Asp (KED) ultrashort vascular peptide bioregulator

Why people care

Peptide bioregulator research focused on vascular endothelial function and gene-regulation pathways.

Human evidence

Preclinical Evidence — The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

Biggest misconception

Key gaps include validated human dosing, pharmacokinetics, long-term safety, clinically meaningful efficacy, product standardization, and independent replication in well-controlled trials.

Bottom line

Vesugen is scientifically interesting for vascular endothelium, vascular aging, but the current case is driven mainly by cell and animal data.

Overview

What is Vesugen?

Vesugen is lys-Glu-Asp (KED) ultrashort vascular peptide bioregulator. Peptide bioregulator research focused on vascular endothelial function and gene-regulation pathways.

Vesugen is a Khavinson ultrashort vascular peptide bioregulator. Research has focused on endothelial-cell proliferation and proposed gene-regulatory effects, with limited human evidence.

Mechanism

How it works

KED is proposed to regulate transcription in vascular cells. Preclinical work reports effects on endothelial proliferation markers and genes involved in vascular homeostasis and aging.

Research areas

vascular endotheliumvascular aginggene regulationcardiovascular biology

Evidence

What does the evidence actually say?

Preclinical Evidence

The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

01

Preclinical Evidence

02

Limited Human Evidence

03

Strong Human Evidence

Human evidence

Human clinical evidence is sparse and not sufficient to establish vascular rejuvenation or cardiovascular-outcome benefits. Most support comes from in vitro, animal, and peptide-bioregulator research.

Preclinical evidence

In vitro and animal studies report effects on endothelial proliferation and expression of genes involved in vascular function and aging. Independent human outcome data are sparse.

Knowledge gaps

Key gaps include validated human dosing, pharmacokinetics, long-term safety, clinically meaningful efficacy, product standardization, and independent replication in well-controlled trials.

Protocol

Research protocol

DoseFrequencyTimingCycle

Dose

community sources experimental reference: 0.5–2 mg/day with gradual titration. No validated human dose exists.

Frequency

Once daily.

Timing

No established time-of-day requirement.

Route

Subcutaneous in the community educational protocol.

Cycle length

8–12 weeks

Reconstitution

Community reference: 2 mL bacteriostatic water per 20 mg vial = 10 mg/mL.

Storage

Community reference: lyophilized at -20 °C; reconstituted 2–8 °C and avoid freeze-thaw.

Monitoring

Blood pressure, cardiovascular risk markers and condition-specific vascular outcomes may be relevant, but no validated Vesugen monitoring standard exists; CBC/CMP are general safety context.

Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.

Safety

Safety, side effects, and precautions

Side effects

Human safety data are insufficient. Potential adverse effects include injection-site reactions, headache, fatigue, dizziness, nausea and unknown long-term effects on gene regulation, growth, metabolism or immune function.

Contraindications

No validated human contraindication profile exists. Avoid use outside research oversight in pregnancy/breastfeeding, active malignancy, significant organ disease or known hypersensitivity.

Interactions

Formal drug-interaction studies are absent or very limited. Interactions with anticancer, endocrine, metabolic and immunomodulatory therapies are unknown.

Stacks

Common stacks

No well-supported stack is highlighted for this peptide yet.

Questions

FAQ

References

Sources

Atlas

The Atlas verdict

Vesugen is scientifically interesting for vascular endothelium, vascular aging, but the current case is driven mainly by cell and animal data. Atlas would treat claimed benefits as hypotheses—not established human outcomes—and would put human safety, product quality, and controlled trials ahead of protocol optimization.

More in Longevity

Longevity

Cortagen

Peptide bioregulator research focused on neuroregeneration, brain aging, and cognitive function.

Read guide

Longevity

Epitalon

Pineal-derived tetrapeptide research exploring telomerase activity, circadian biology, and healthy aging.

Read guide

Longevity

FOXO4-DRI

Experimental senolytic peptide research investigating selective removal of senescent cells.

Read guide